Role of a novel pyridostigmine bromide-phospholipid nanocomplex in improving oral bioavailability

Archives of Pharmacal Research

Volumn 35, Issue 3, 2012, Pages 499-508

  Tan, Qun You ^a   Hu, Ni Ni ^b   Liu, Guo Dong ^a   Yin, Hua Feng ^b   Zhang, Li ^b   Wang, Hong ^b   Lu, Lu Yang ^c   Zhang, Jing Qing ^b  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c SOUTHWEST UNIVERSITY FOR NATIONALITIES   (China)

Author keywords

Bioavailability; Central composite design; Lipophilicity; Phospholipid complex; Pyridostigmine bromide

Indexed keywords

OCTANE; PHOSPHOLIPID; PYRIDOSTIGMINE; WATER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CHEMICAL COMPOSITION; COMPLEX FORMATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROSCOPY; INTESTINE MUCOSA PERMEABILITY; INTESTINE PERFUSION; MALE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR INTERACTION; NONHUMAN; PARTICLE SIZE; PARTITION COEFFICIENT; PLASMA CONCENTRATION-TIME CURVE; PROCESS OPTIMIZATION; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRAVIOLET SPECTROSCOPY; ZETA POTENTIAL;

1-OCTANOL; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CHOLINESTERASE INHIBITORS; DRUG COMPOUNDING; INTESTINAL ABSORPTION; INTESTINES; LINEAR MODELS; MALE; MODELS, BIOLOGICAL; NANOPARTICLES; NANOTECHNOLOGY; PERMEABILITY; PHOSPHOLIPIDS; PYRIDOSTIGMINE BROMIDE; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SOLVENTS; SPECTROPHOTOMETRY, ULTRAVIOLET; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TECHNOLOGY, PHARMACEUTICAL; WATER;

EID: 84862881741     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-012-0313-6     Document Type: Article

References (36)

1. Banerjee, T., Maitra, S., Kumar, S. A., Kumar, S. R., and Maitra, A., Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles. Int. J. Pharm., 243, 93-105 (2002).
2. Barak, D., Ordentlich, A., Stein, D., Yu, Q. S., Greig, N. H., and Shafferman, A., Accommodation of physostigmine and its analogues by acetylcholinesterase is dominated by hydrophobic interactions. Biochem. J., 417, 213-222 (2009).
3. Bombardelli, E., Curri, S. B., Della, L. R., Del, N. P., Tubaro, A., and Gariboldi, P., Complex between phospholipids and vegetal derivatives of biological interest. Fitoterapia, 60, 1-9 (1989).
4. Bombardelli, E., Phytosome: new cosmetic delivery system. Boll. Chim. Farm., 130, 431-438 (1991).
5. Dahan, A., West, B. T., and Amidon, G. L., Segmentaldependent membrane permeability along the intestine following oral drug administration: Evaluation of a triple single-pass intestinal perfusion (TSPIP) approach in the rat. Eur. J. Pharm. Sci., 36, 320-329 (2009).
6. Di Pierro, F., Menghi, A. B., Barreca, A., Lucarelli, M., and Calandrelli, A., Greenselect Phytosome as an adjunct to a low-calorie diet for treatment of obesity: a clinical trial. Altern. Med. Rev., 14, 154-160 (2009).
7. Fagerholm, U., Johansson, M., and Lennernas, H., Comparison between permeability coefficients in rat and human jejunum. Pharm. Res., 13, 1336-1342 (1996).
8. Ferreira, S. L., Bruns, R. E., David, J. M., Silva, E. G., Santos, W. N., Quintella, C. M., Andrade, J. B., Breitkreitz, M. C., Jardim, I. C., and Neto, B. B., Statistical designs and response surface techniques for the optimization of chromatographic systems. J. Chromatogr. A, 1158, 2-14 (2007).
9. Flaig, T. W., Glode, M., Gustafson, D., Bokhoven, A., Tao, Y., Wilson, S., Su, L. J., Li, Y., and Harrison, G., A study of highdose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate, 70, 848- 855 (2010).
10. Giacomelli, S., Gallo, D., Apollonio, P., Ferlini, C., Distefano, M., Morazzoni, P., Riva, A., and Bombardelli, E., Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo the activity of cisplatin. Life Sci., 70, 1447-1459 (2002).
11. Huang, Y. T., Tsai, T. R., Cheng, C. J., Cham, T. M., Lai, T. F., and Chuo, W. H., Formulation design of a highly hygroscopic drug (pyridostigmine bromide) for its hygroscopic character improvement and investigation of in vitro/in vivo dissolution properties. Drug Dev. Ind. Pharm., 33, 403-416 (2007).
12. Husain, M. A., Roberts, J. B., Thomas, B. H., and Wilson, A., The excretion and metabolism of oral 14C-pyridostigmine in the rat. Br. J. Pharmacol., 34, 445-450 (1968).
13. Jeong, S. E., Park, J. K., Kim, J. D., Chang, I. J., Hong, S. J., Kang, S. H., and Lee, C. G., Statistical optimization of the growth factors for chaetoceros neogracile using fractional factorial design and central composite design. J. Microbiol. Biotechnol., 18, 1919-1926 (2008).
14. Kidd, P. and Head, K., A review of the bioavailability and clinical effcacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (siliphos). Altern. Med. Rev., 10, 193-203 (2005).
15. Kidd, P. M., Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts. Altern. Med. Rev., 14, 226-246 (2009).
16. Kim, J. S., Mitchell, S., Kijek, P., Tsume, Y., Hilnger, J., and Amidon, G. L., The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests. Mol. Pharm., 3, 686-694 (2006).
17. Li, M., Si, L. Q., Pan, H. P., Rabba, A. K., Yan, F., Qiu, J., and Li, G., Excipients enhance intestinal absorption of ganciclovir by P-gp inhibition: Assessed in vitro by everted gut sac and in situ by improved intestinal perfusion. Int. J. Pharm., 403, 37-45 (2011).
18. Lian, J. and Wang, B. C., Studies on technical Metewand of phytosome process and its applications. Letters In Biotechnology, 17, 830-833 (2006).
19. Ling, P. X., You, X., Wang, F. S., Zhu, M. H., and Zhang, T. M., Recent research of drug-phospholipid complexes. Chin. Pharm. J., 40, 401-402 (2005).
20. Maiti, K., Mukherjee, K., Gantait, A., and Saha, B. P., Curcumin- phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. Int. J. Pharm., 330, 155-163 (2007).
21. Martins, S. A., Prazeres, D. M., Fonseca, L. P., and Monteiro, G. A., Application of central composite design for DNA hybridization onto magnetic microparticles. Anal. Biochem., 391, 17-23 (2009).
22. Peng, Q., Gong, T., Zuo, J., Liu, J., Zhao, D., and Zhang, Z., Enhanced oral bioavailability of salvianolic acid B by phospholipid complex loaded nanoparticles. Pharmazie, 63, 661-666 (2008).
23. Peng, Q., Zhang, Z. R., Sun, X., Zuo, J., Zhao, D., and Gong, T., Mechanisms of phospholipid complex loaded nanoparticles enhancing the oral bioavailability. Mol. Pharm., 7, 565-575 (2010).
24. Qin, X., Yang, Y., Fan, T. T., Gong, T., Zhang, X. N., and Huang, Y., Preparation, characterization and in vivo evaluation of bergenin-phospholipid complex. Acta Pharmacol. Sin., 31, 127-136 (2010).
25. Shi, Y. J., Wu, P. J., and Wei, P., Optimization on preparation of hawthorn fruit total flavonoids-phospholipid complex using Plackett-Burman design, central composite design and response surface methodology. Zhong Yao Cai, 33, 437-441 (2010).
26. Tan, Q. Y., Wang, N., Yang, H., Zhang, L. K., Liu, S., Chen, L., Liu, J., Zhang, L., Hu, N. N., Zhao, C. J., and Zhang, J. Q., Characterization, stabilization and activity of uricase loaded in lipid vesicles. Int. J. Pharm., 384, 165-172 (2010a).
27. Tan, Q. Y., Wang, N., Yang, H., Chen, L., Xiong, H. R., Zhang, L. K., Liu, J., Zhao, C. J., and Zhang, J. Q., Preparation and characterization of lipid vesicles containing uricase. Drug Deliv., 17, 28-37 (2010b).
28. Tsapatsaris, S. and Kotzekidou, P., Application of central composite design and response surface methodology to the fermentation of olive juice by Lactobacillus plantarum and Debaryomyces hansenii. Int. J. Food Microbiol., 95, 157-161 (2004).
29. Wu, X. G., Li, G., and Gao, Y. L., Optimization of the preparation of nalmefene-loaded sustained-release microspheres using central composite design. Chem. Pharm. Bull. (Tokyo), 54, 977-981 (2006).
30. Xiao, Y. Y., Song, Y. M., Chen, Z. P., and Ping, Q. N., Preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats. Int. J. Pharm., 307, 77-82 (2006).
31. Xu, K. Y., Liu, B. G., Ma, Y. X., Du, J. Q., Li, G. G., Gao, H., Zhang, Y., and Ning, Z. X., Physicochemical properties and antioxidant activities of luteolin-phospholipid complex. Molecules, 14, 3486-3493 (2009).
32. Yue, P. F., Zhang, W. J., Yuan, H. L., Yang, M., Zhu, W. F., Cai, P. L., and Xiao, X. H., Process optimization, characterization and pharmacokinetic evaluation in rats of ursodeoxycholic acid-phospholipid complex. AAPS PharmSci- Tech, 9, 322-329 (2008).
33. Yue, P. F., Yuan, H. L., Li, X. Y., Yang, M., and Zhu, W. F., Process optimization, characterization and evaluation in vivo of oxymatrine-phospholipid complex. Int. J. Pharm., 387, 139-146 (2010).
34. Zhang, J. Q., Zhang, Z. R., Yang, H., Tan, Q. Y., Qing, S. R., and Qiu, X. L., Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: in vitro and in vivo studies. Pharm. Res., 22, 573-583 (2005).
35. Zhang, J. Q., Liu, J., Li, X. L., and Jasti, B. R., Preparation and characterization of solid lipid nanoparticles containing silibinin. Drug Deliv., 14, 381-387 (2007).
36. Zhao, B., Moochhala, S. M., Lu, J., Tan, D., and Lai, M. H., Determination of pyridostigmine bromide and its metabolites in biological samples. J. Pharm. Pharmaceut. Sci., 9, 71-81 (2006).